Geriatric electrophysiology and better device therapy decisions

Older adults with arrhythmias are among the most complex patients in contemporary cardiac care. Atrial fibrillation, bradyarrhythmia, ventricular tachycardia and conduction disease often coexist with multimorbidity, cognitive impairment, mobility limitations and polypharmacy. The decision to implant a pacemaker, implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation device therefore involves more than an electrocardiogram or an age threshold.

Geriatric electrophysiology brings a broader clinical lens to these decisions. It considers whether a patient can tolerate a procedure, manage wound care, attend device checks and benefit from the expected years of therapy. It also recognises that an apparently small decline in mobility or cognition may alter recovery, independence and quality of life after implantation.

Frailty assessment provides a practical way to identify vulnerability before an intervention. Used alongside rhythm diagnosis, ventricular function, comorbidity and patient goals, it can support shared decision-making without becoming a reason to deny effective treatment. The aim is proportional care: appropriate therapy for the person, not simply treatment of the device indication.

For clinicians, trainees and researchers, the open-access Journal of Arrhythmia provides a valuable setting for following developments in pacing, ablation, implantable devices and arrhythmia pharmacology. Its relevance is especially clear as health systems address ageing populations, longer survival with chronic disease and growing demand for electrophysiology services.

Why age changes the electrophysiology pathway

Ageing affects the cardiovascular system in ways that influence both arrhythmia expression and procedural risk. Fibrosis of the conduction system may cause sinus node dysfunction or atrioventricular block, while atrial remodelling increases the likelihood of atrial fibrillation. Older patients also have higher rates of chronic kidney disease, heart failure, diabetes, respiratory disease and previous stroke. Each condition can affect anaesthesia, anticoagulation, infection risk or the ability to recover at home.

Chronological age alone is an unreliable guide. An active 84-year-old who lives independently may recover rapidly from a pacemaker procedure, whereas a 72-year-old with sarcopenia, recurrent falls and cognitive impairment may face a prolonged hospital stay. Australian services encounter this variation across metropolitan centres such as Sydney, Melbourne and Brisbane, as well as in regional communities where travel for implantation and follow-up can be demanding.

A device recommendation should therefore include a review of symptom burden, likely survival, functional goals and the reversibility of the presenting problem. A pacemaker may relieve syncope caused by high-grade block, while an ICD may prevent sudden death in a patient with meaningful life expectancy and a suitable risk profile. Conversely, an intervention with limited expected benefit may impose wound complications, shocks, restrictions and repeated hospital contact.

Frailty is more than a chronological label

Frailty describes reduced physiological reserve and a limited ability to withstand stress. It is distinct from disability, although the two frequently overlap. A person may have a disability and remain physiologically robust, while a patient who appears independent may have early frailty that becomes visible only after a procedure or acute admission.

Common indicators include unintentional weight loss, exhaustion, slow gait speed, weak grip strength, low physical activity and difficulty rising from a chair. Multidomain frailty also incorporates cognition, mood, nutrition, medication burden, social support and functional dependence. These features can predict mortality, delirium, prolonged admission and loss of independence after cardiovascular procedures more effectively than age by itself.

Assessment should be respectful and clinically useful rather than a bureaucratic exercise. Asking how a patient manages shopping, transport, medications, showering and household tasks may reveal more than a long medical history. In Australia, the assessment may need to account for a patient who relies on an adult child in Perth, receives support through My Aged Care in Adelaide or travels from a rural town to a tertiary hospital for device review.

Frailty is also dynamic. Treatable contributors such as anaemia, dehydration, malnutrition, medication adverse effects, poor vision or an untreated infection can worsen apparent vulnerability. Reassessment after optimisation may identify patients who can proceed safely, while persistent severe frailty may prompt a different device strategy or a goals-of-care discussion.

Choosing the right assessment tools

Several tools can be integrated into an electrophysiology workflow. The Clinical Frailty Scale offers a rapid global rating based on function and activity, while the Fried phenotype focuses on physical features such as weakness, slowness and weight loss. A timed up-and-go test, gait speed, chair-rise assessment and basic nutritional screening add objective information without requiring a lengthy geriatric consultation.

No single scale captures every relevant outcome. Cognitive screening is important when patients must understand remote monitoring, recognise wound problems or report ICD shocks. Medication review can identify sedatives, hypotensive agents, anticoagulants and drugs that increase falls risk. Social assessment should establish who can provide transport, observe the wound and assist during the first days after discharge.

A practical pre-procedure pathway can begin with a brief frailty screen in the arrhythmia clinic. Patients with concerning findings can then receive a more detailed assessment involving geriatric medicine, nursing, pharmacy, physiotherapy or occupational therapy. This tiered approach is more feasible than referring every older patient for a comprehensive assessment and may be particularly useful in busy public hospitals.

Assessment results should be documented in terms that guide action. “Clinical Frailty Scale 6” has value, but “needs assistance with dressing, walks outdoors with a stick and has no reliable transport” is more useful for discharge planning. Functional detail also helps researchers compare populations and interpret outcomes across studies.

Device therapy outcomes in real-world patients

Pacemaker implantation generally has a high technical success rate, yet frailty can influence recovery, complications and long-term benefit. Vulnerable patients may experience delirium, falls, deconditioning, pocket haematoma or infection. A short procedure can still lead to a major decline if it interrupts mobility or separates a person from their usual support network.

ICD outcomes require an especially careful balance. An ICD can reduce sudden cardiac death in selected patients, but it may deliver shocks that are painful and distressing. Advanced heart failure, progressive cancer, severe cognitive impairment or limited functional status may reduce the likelihood that the device will provide meaningful benefit. Discussions should cover shock treatment, deactivation near the end of life and the difference between turning off shock therapy and stopping pacing support.

Cardiac resynchronisation therapy may improve symptoms and ventricular function in selected patients, but response depends on underlying disease, lead position, adherence to medical therapy and competing illness. The potential gain should be considered alongside the burden of a longer procedure, venous access challenges and future generator or lead interventions.

Australian registries and local device databases can help reveal outcomes that clinical trials may underrepresent. The device market includes established transvenous systems, leadless pacemakers, subcutaneous ICDs and remote monitoring platforms, but access and funding can differ between public and private settings. Cost, device availability, battery longevity and the patient’s ability to use connected technology all belong in the discussion.

Designing safer implantation and follow-up

Frailty-informed care begins before the procedure. Correcting dehydration, reviewing anticoagulation, treating infection, improving nutrition and planning delirium prevention can reduce avoidable harm. Clear communication about fasting, medication changes and post-procedure restrictions is essential when hearing loss, language barriers or cognitive impairment are present.

The procedural environment can also be adapted. Regional or local anaesthesia may be preferable for some patients, although the choice depends on the device and clinical circumstances. Minimising unnecessary lines and sedatives, maintaining orientation, supporting early mobilisation and involving family or carers can protect function during the admission.

Discharge planning should start before implantation. Patients need written instructions on wound care, arm movement, infection symptoms and when to seek urgent help. Follow-up arrangements should reflect geography and transport. Telehealth and remote monitoring may reduce trips from regional New South Wales or northern Queensland, but they cannot replace in-person assessment for wound concerns, frailty progression or patients who lack internet access.

Shared decision-making should include the future, not just the procedure. A patient may accept implantation to remain at home with a partner, attend a granddaughter’s wedding or avoid recurrent syncope. Another may prioritise comfort and freedom from hospital visits. Recording these priorities supports later decisions about generator replacement, lead revision, ICD shock management and escalation of care.

Building evidence for Australian practice

Research in older electrophysiology patients should report more than procedural success. Important outcomes include delirium, hospital-free days, falls, readmission, loss of independence, quality of life, caregiver burden and device-related complications. Mortality remains relevant, but it should be interpreted alongside whether treatment preserved the activities and relationships that mattered to the patient.

Studies should describe frailty using transparent methods and include patients with multimorbidity, cognitive impairment and reduced mobility. Excluding these groups creates evidence that is easier to analyse but less applicable to everyday Australian practice. Subgroup reporting by age, sex, rurality, socioeconomic status and Aboriginal and Torres Strait Islander identity can also expose inequities in access and follow-up.

Clinical teams can use multidisciplinary case conferences to connect electrophysiology with geriatric medicine, heart failure, pharmacy, rehabilitation and palliative care. Such collaboration is valuable in tertiary centres including Royal Melbourne Hospital and Westmead, but it can also be supported through outreach networks and telehealth for smaller services. The focus should remain practical: selecting patients, preparing them well and measuring outcomes that matter after discharge.

Readers looking for focused evidence can explore themed collections on arrhythmia management, devices and electrophysiology. Publishing carefully characterised geriatric cohorts, implementation studies and patient-centred outcomes will help move the field beyond age-based assumptions.

A frailty-informed device pathway can make treatment safer, more transparent and more humane. Electrophysiology teams can begin by adding a brief functional screen, documenting patient priorities, involving carers early and reviewing outcomes after discharge. Researchers can strengthen the evidence base by reporting function and quality of life alongside survival and procedural success. Clinicians, trainees and investigators across Australia are encouraged to apply these principles in practice and contribute robust findings to the continuing discussion on rhythm care for older adults.